Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : IND approval

AK0406: New Long-Acting Influenza Antiviral Approved in China

AK0406: New Long-Acting Influenza Antiviral Approved in China
08/18/2026 | Companies
Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza...
AFC, AK0406, antigenic drift, antiviral drug, antiviral drug-Fc conjugate, antiviral therapy, ArkBio, Australia, biopharmaceuticals, China, clinical development, drug development, global clinical development, HREC, IND approval, infectious diseases, influenza, influenza A, influenza B, influenza prevention, influenza prophylaxis, influenza vaccines, long-acting antiviral, NMPA, Phase I clinical trial, preclinical studies, prophylactic treatment, seasonal influenza, Shanghai Ark Biopharmaceutical, therapeutic treatment

Vimgreen Secures IND Approval for VG081821 in NASH Treatment

Vimgreen Secures IND Approval for VG081821 in NASH Treatment
03/18/2026 | Companies
Vimgreen Pharmaceuticals, a prominent company focused on modulating adenosine signaling pathways, has announced that China’s Center for Drug Evaluation (CDE) has cleared its Investigational New Drug (IND) application for VG081821 in non-alcoholic steatohepatitis (NASH), now more commonly termed...
A2A receptor antagonist, adenosine signalling, biotechnology, China CDE, clinical trials, drug development, fibrosis, hepatology, IND approval, inflammation, inverse agonist, lipophagy, liver disease, MASH, metabolic disorders, metabolic dysfunction associated steatohepatitis, NASH, non alcoholic steatohepatitis, Parkinsons disease, Phase II trial, resmetirom, semaglutide, steatosis, VG081821, Vimgreen Pharmaceuticals


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com